Tags

Type your tag names separated by a space and hit enter

A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis.
Front Immunol. 2020; 11:588079.FI

Abstract

Berberine (BBR) has been reported that it has effects on inhibiting colorectal cancer (CRC). However, the mechanism of BBR on CRC also remains largely unknown. Herein, we investigated the therapeutic effects of BBR on CRC from the perspective of gut microbiota and metabolic alterations, which can provide a holistic view to understand the effects of BBR on CRC. First, azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse was used as CRC animal model, then the degree of colorectal carcinogenesis in AOM/DSS mice with or without BBR administration was measured. The composition and abundance of gut microbiota was investigated by using 16S rRNA. Meanwhile, feces samples were analyzed with 1H NMR spectroscopy to investigate the metabolic alterations. As a result, BBR significantly reduced intestinal tumor development with lower macroscopic polyps and ki-67 expression of intestinal tissue, and better colonic morphology in mice. Moreover, BBR altered the composition of gut microbiota in AOM/DSS mice obviously, which were characterized by a decrease of Actinobacteria and Verrucomicrobia significantly at the phylum level. At the genus level, it was able to suppress pathogenic species, such as f_Erysipelotrichaceae, Alistipes, and elevate some short-chain fatty acids (SCFA)-producing bacteria, including Alloprevotella, Flavonifractor, and Oscillibacter. Metabolic data further revealed that BBR induced metabolic changes in feces focus on regulating glycometabolism, SCFA metabolism and amino acid metabolism, which also provides evidence for alteration of the microbiota because these feces metabolites are the products of interactions between the host and the microbial community. This study showed that BBR induced alterations in microbiota and metabolic in AOM/DSS mice, which might providing new insight into the inhibition effects of BBR on CRC.

Authors+Show Affiliations

The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.Department of Integrated Traditional Chinese and Western Medicine, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33072135

Citation

Chen, Haitao, et al. "A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based On Microbiome-Metabolomics Analysis." Frontiers in Immunology, vol. 11, 2020, p. 588079.
Chen H, Zhang F, Zhang J, et al. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis. Front Immunol. 2020;11:588079.
Chen, H., Zhang, F., Zhang, J., Zhang, X., Guo, Y., & Yao, Q. (2020). A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis. Frontiers in Immunology, 11, 588079. https://doi.org/10.3389/fimmu.2020.588079
Chen H, et al. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based On Microbiome-Metabolomics Analysis. Front Immunol. 2020;11:588079. PubMed PMID: 33072135.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis. AU - Chen,Haitao, AU - Zhang,Fan, AU - Zhang,Jin, AU - Zhang,Xinjie, AU - Guo,Yong, AU - Yao,Qinghua, Y1 - 2020/09/24/ PY - 2020/07/28/received PY - 2020/09/02/accepted PY - 2020/10/19/entrez PY - 2020/10/20/pubmed PY - 2021/7/17/medline KW - NMR-based metabolomics KW - berberine KW - colorectal cancer KW - gut microbiota KW - metabolites SP - 588079 EP - 588079 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - Berberine (BBR) has been reported that it has effects on inhibiting colorectal cancer (CRC). However, the mechanism of BBR on CRC also remains largely unknown. Herein, we investigated the therapeutic effects of BBR on CRC from the perspective of gut microbiota and metabolic alterations, which can provide a holistic view to understand the effects of BBR on CRC. First, azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse was used as CRC animal model, then the degree of colorectal carcinogenesis in AOM/DSS mice with or without BBR administration was measured. The composition and abundance of gut microbiota was investigated by using 16S rRNA. Meanwhile, feces samples were analyzed with 1H NMR spectroscopy to investigate the metabolic alterations. As a result, BBR significantly reduced intestinal tumor development with lower macroscopic polyps and ki-67 expression of intestinal tissue, and better colonic morphology in mice. Moreover, BBR altered the composition of gut microbiota in AOM/DSS mice obviously, which were characterized by a decrease of Actinobacteria and Verrucomicrobia significantly at the phylum level. At the genus level, it was able to suppress pathogenic species, such as f_Erysipelotrichaceae, Alistipes, and elevate some short-chain fatty acids (SCFA)-producing bacteria, including Alloprevotella, Flavonifractor, and Oscillibacter. Metabolic data further revealed that BBR induced metabolic changes in feces focus on regulating glycometabolism, SCFA metabolism and amino acid metabolism, which also provides evidence for alteration of the microbiota because these feces metabolites are the products of interactions between the host and the microbial community. This study showed that BBR induced alterations in microbiota and metabolic in AOM/DSS mice, which might providing new insight into the inhibition effects of BBR on CRC. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/33072135/A_Holistic_View_of_Berberine_Inhibiting_Intestinal_Carcinogenesis_in_Conventional_Mice_Based_on_Microbiome_Metabolomics_Analysis_ L2 - https://doi.org/10.3389/fimmu.2020.588079 DB - PRIME DP - Unbound Medicine ER -